Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05999383 · ClinicalTrials.gov registry record · Phase 2

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

A Phase 2 study of Tobacco Use and Cannabis Use, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT05999383: Recruiting Phase 2 study of Tobacco Use and Cannabis Use, sponsored by University of California, San Francisco.

NCT05999383 is a Phase 2 study of Tobacco Use and Cannabis Use that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 48 participants, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05999383, a Phase 2 study of Tobacco Use and Cannabis Use, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

Primary Outcome

To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.

Interventions

  • DRUG Nicotine
  • DRUG Cannabis
  • DEVICE Pax Loose Leaf Vaporizer
  • OTHER Placebo Marijuana

Study Locations (1)

California

  • Zuckerberg San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-07-01
Est. Completion 2028-02-01
Phase Phase 2

What NCT05999383 shows while recruiting

NCT05999383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower).

The record links to 6 conditions, with Tobacco Use appearing as the primary indexed condition, and to 4 interventions - of which Nicotine is the first listed.

NCT05999383 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05999383 about?

NCT05999383 is a clinical study titled "Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration". This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-admin...

What is the current status of trial NCT05999383?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2025-07-01. Estimated completion is 2028-02-01.

What conditions does trial NCT05999383 study?

This clinical trial studies the following conditions: Tobacco Use, Cannabis Use, Cannabis, Vaping, THC.

What interventions are being tested in trial NCT05999383?

The interventions under investigation include: Nicotine (DRUG), Cannabis (DRUG), Pax Loose Leaf Vaporizer (DEVICE), Placebo Marijuana (OTHER).

Who is sponsoring clinical trial NCT05999383?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05999383 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05999383's enrollment target sits among peer trials

48 57th of 76 higher than 20 of 76 other Tobacco Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05999383, the US trial registry maintained by the National Library of Medicine. NCT05999383 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.